JWH-175: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:JWH-175}} | |||
== | == Overview == | ||
'''JWH-175''' is a synthetic cannabinoid that acts as a potent agonist at the [[cannabinoid receptor|cannabinoid receptors]]. It is part of the [[naphthoylindole]] family of compounds, which are known for their psychoactive effects. JWH-175 was developed by Dr. [[John W. Huffman]] and his team at [[Clemson University]] as part of their research into the structure and function of cannabinoid receptors. | |||
== Chemical Structure == | |||
[[File:JWH-175.svg|thumb|right|Chemical structure of JWH-175]] | |||
JWH-175 is characterized by its naphthoylindole structure, which includes a naphthalene ring linked to an indole group. The specific chemical formula for JWH-175 is C24H23NO, and it has a molecular weight of 341.45 g/mol. The compound is known for its high affinity for the [[CB1 receptor|CB1]] and [[CB2 receptor|CB2]] receptors, which are part of the [[endocannabinoid system]]. | |||
== Pharmacology == | == Pharmacology == | ||
JWH-175 functions as a full agonist at both the CB1 and CB2 receptors. These receptors are part of the [[G protein-coupled receptor]] family and are primarily involved in the modulation of neurotransmitter release in the [[central nervous system]] and [[peripheral nervous system]]. The activation of these receptors by JWH-175 can lead to a variety of effects, including [[analgesia]], [[anti-inflammatory]] effects, and psychoactive effects similar to those of [[tetrahydrocannabinol]] (THC), the active component of [[cannabis]]. | |||
JWH-175 | |||
== Legal Status == | == Legal Status == | ||
The legal status of JWH-175 varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of medical use. The compound is often included in legislation targeting synthetic cannabinoids, which are frequently used as recreational drugs. | |||
The | == Synthesis == | ||
The synthesis of JWH-175 involves the condensation of a naphthoyl chloride with an indole derivative. This process is similar to the synthesis of other naphthoylindole compounds and requires careful control of reaction conditions to ensure the desired product is obtained. | |||
== | == Potential Uses == | ||
While JWH-175 and similar compounds have been primarily studied for their recreational use, there is ongoing research into their potential therapeutic applications. These include the treatment of [[chronic pain]], [[neuropathic pain]], and [[inflammatory disorders]]. However, the psychoactive effects and potential for abuse limit their use in clinical settings. | |||
== Related Pages == | |||
* [[Synthetic cannabinoids]] | * [[Synthetic cannabinoids]] | ||
* [[Cannabinoid receptor]] | * [[Cannabinoid receptor]] | ||
* [[John W. Huffman]] | |||
* [[Naphthoylindole]] | |||
[[Category:Synthetic cannabinoids]] | [[Category:Synthetic cannabinoids]] | ||
[[Category: | [[Category:Chemical compounds]] | ||
Latest revision as of 04:04, 13 February 2025
Overview[edit]
JWH-175 is a synthetic cannabinoid that acts as a potent agonist at the cannabinoid receptors. It is part of the naphthoylindole family of compounds, which are known for their psychoactive effects. JWH-175 was developed by Dr. John W. Huffman and his team at Clemson University as part of their research into the structure and function of cannabinoid receptors.
Chemical Structure[edit]
JWH-175 is characterized by its naphthoylindole structure, which includes a naphthalene ring linked to an indole group. The specific chemical formula for JWH-175 is C24H23NO, and it has a molecular weight of 341.45 g/mol. The compound is known for its high affinity for the CB1 and CB2 receptors, which are part of the endocannabinoid system.
Pharmacology[edit]
JWH-175 functions as a full agonist at both the CB1 and CB2 receptors. These receptors are part of the G protein-coupled receptor family and are primarily involved in the modulation of neurotransmitter release in the central nervous system and peripheral nervous system. The activation of these receptors by JWH-175 can lead to a variety of effects, including analgesia, anti-inflammatory effects, and psychoactive effects similar to those of tetrahydrocannabinol (THC), the active component of cannabis.
Legal Status[edit]
The legal status of JWH-175 varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of medical use. The compound is often included in legislation targeting synthetic cannabinoids, which are frequently used as recreational drugs.
Synthesis[edit]
The synthesis of JWH-175 involves the condensation of a naphthoyl chloride with an indole derivative. This process is similar to the synthesis of other naphthoylindole compounds and requires careful control of reaction conditions to ensure the desired product is obtained.
Potential Uses[edit]
While JWH-175 and similar compounds have been primarily studied for their recreational use, there is ongoing research into their potential therapeutic applications. These include the treatment of chronic pain, neuropathic pain, and inflammatory disorders. However, the psychoactive effects and potential for abuse limit their use in clinical settings.
